Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20434854 | 0.88 | CRHBP (0.41) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL12445299 | 0.81 | CRHBP (0.39) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL20434848 | 0.80 | CRHBP (0.36) | CRHBPCRHR2 | |
| SCHEMBL12127018 | 0.79 | CRHBP (0.38) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL680662 | 0.78 | GRIN2D (0.36) | CRHBPCRHR2 | |
| SCHEMBL17170028 | 0.78 | CRHBP (0.39) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL25094028 | 0.78 | — | — | |
| SCHEMBL24928385 | 0.77 | CRHBP (0.37) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL20434849 | 0.77 | CRHBP (0.37) | CRHBPCRHR2ALDH1A1 | |
| SCHEMBL19504471 | 0.76 | CRHBP (0.33) | CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | VERNALIS (R&D) LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | CRHBP 4600/4885CRHR2 4320/4885ALDH1A1 1144/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | CRHBP 1691/4885CRHR2 4043/4885ALDH1A1 2297/4885 |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | CRHBP 2722/4885CRHR2 3333/4885ALDH1A1 2908/4885 |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | HSP90AA1, HSP90AB1, HSP90AB2P | CRHBP 2334/4885CRHR2 2101/4885ALDH1A1 1275/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | CRHBP 4068/4885CRHR2 3932/4885ALDH1A1 1715/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CRHBP 808/4885CRHR2 1030/4885ALDH1A1 4740/4885 |
| US-20100010037-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | CRHBP 2023/4885CRHR2 818/4885ALDH1A1 1315/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | CRHBP 3431/4885CRHR2 2754/4885ALDH1A1 876/4885 |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | CRHBP 1647/4885CRHR2 2506/4885ALDH1A1 773/4885 |
| US-20070254901-A1 | Inhibitors of Akt Activity | AKT1, AKT2, PIK3CD | CRHBP 4383/4885CRHR2 4658/4885ALDH1A1 3440/4885 |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | BDKRB2, BDKRB1, TRPV1 | CRHBP 1707/4885CRHR2 717/4885ALDH1A1 2173/4885 |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | CRHBP 1482/4885CRHR2 2925/4885ALDH1A1 759/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | CRHBP 864/4885CRHR2 314/4885ALDH1A1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.